Inozyme Pharma, Inc. announced that Dr. Kurt Gunter, the company's Senior Vice President and Chief Medical Officer, will present data on the Expanded Access Program for their therapeutic candidate INZ ...
- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback